Explain the phenomena of Parkinsonism. What is difference between wearing off phenomena and on-off phenomena?
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have all the information needed from the textbooks to give a thorough answer. Let me compile this.
Parkinsonism: The Syndrome
Parkinsonism is a clinical syndrome - not a single disease - defined by the combination of specific motor features that result from disruption of dopaminergic pathways, particularly within the basal ganglia. The term describes any condition sharing these cardinal features, of which Parkinson's disease (PD) is the most common cause (~75% of cases).
Cardinal Features (TRAP)
| Feature | Description |
|---|---|
| T - Tremor at rest | "Pill-rolling" tremor (3-6 Hz), present at rest, diminishes with voluntary movement |
| R - Rigidity | Increased muscle tone throughout range of motion; may show "cogwheel" quality due to superimposed tremor |
| A - Akinesia / Bradykinesia | Absence or slowness of movement; poverty of spontaneous movement |
| P - Postural instability | Loss of righting reflexes; festinating gait, retropulsion, falls |
Bradley & Daroff lists six cardinal features: (1) tremor at rest, (2) bradykinesia, (3) rigidity, (4) loss of postural reflexes, (5) flexed posture, and (6) freezing (motor blocks).
Pathophysiology
PD results from loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), with resultant abnormal neuronal activity in both the direct and indirect basal ganglia pathways. Decreased dopaminergic input to the striatum leads to increased inhibitory output from basal ganglia to the thalamus, causing the hypokinetic motor disorder.
- Pathological hallmark: Lewy bodies (intraneuronal inclusions containing alpha-synuclein)
- Genetics: Mutations in SNCA, PARK2 (parkin), LRRK2, PINK1 genes are identified causes
Associated (Non-Motor) Features
- Masked facies (hypomimia), reduced blink rate
- Micrographia (small handwriting)
- Hypophonia (soft, hurried speech)
- Sialorrhea (drooling)
- Anosmia (often a premotor symptom, years before motor onset)
- Autonomic dysfunction: orthostatic hypotension, constipation, urinary incontinence
- Neuropsychiatric: depression, anxiety, dementia (15-40% late in disease), REM sleep behavior disorder
Causes of Parkinsonism
| Category | Examples |
|---|---|
| Idiopathic | Parkinson's disease (most common) |
| Drug-induced | Dopamine antagonists (haloperidol, prochlorperazine, metoclopramide) |
| Atypical (Parkinson-plus) | MSA (multiple system atrophy), PSP (progressive supranuclear palsy) |
| Vascular | Vascular parkinsonism |
| Dementia syndromes | Dementia with Lewy bodies, PD dementia |
| Toxic | MPTP, manganese, CO poisoning |
| Postencephalitic | Following encephalitis |
| Genetic | SNCA, LRRK2, PARK2 mutations |
Motor Fluctuations in Parkinson's Disease: Wearing Off vs. On-Off
After years of levodopa therapy (dyskinesias occur in up to 80% of patients receiving levodopa for >10 years), motor fluctuations develop. These are of two distinct types:
1. Wearing-Off Phenomenon (End-of-Dose Akinesia)
Definition: Fluctuations in motor control that are directly related to the timing of levodopa doses - the drug effect wears out before the next dose is due.
Mechanism:
- As PD progresses, the number of dopaminergic neurons (which used to "buffer" dopamine levels) declines dramatically
- The brain becomes dependent on the plasma half-life of levodopa (~90 minutes)
- At the end of each dosing interval, plasma levodopa levels fall below the therapeutic threshold
- The patient predictably deteriorates ("goes off") before the next scheduled dose
Key features:
- Predictable - patient and clinician can anticipate when it will occur
- Directly correlated with dose timing
- Patient transitions from "on" (mobile, functional) back to parkinsonism symptoms near the end of each dosing interval
- Symptoms: re-emergence of bradykinesia, rigidity, tremor, dystonia (especially early morning "off-period dystonia" in the more severely affected foot before the first daily dose)
Management:
- Increase levodopa dose frequency (smaller, more frequent doses)
- Add a COMT inhibitor (entacapone, opicapone) - reduces peripheral breakdown of levodopa, smoothing levels
- Add an MAO-B inhibitor (selegiline, rasagiline, safinamide) - reduces dopamine breakdown in the brain
- Use sustained-release levodopa formulations
- Add a dopamine agonist
2. On-Off Phenomenon
Definition: Fluctuations in clinical state that are unrelated to the timing of levodopa doses - unpredictable swings between states.
Mechanism:
- Exact mechanism is unknown
- Thought to involve abnormal regulation of dopamine levels combined with an abnormal physiological response to intermittent exogenous dosing, leading to an unstable network
- Likely involves altered pharmacodynamics at post-synaptic dopamine receptors, not just pharmacokinetics
- Most commonly occurs in patients who initially responded very well to levodopa
Key features:
- Unpredictable - no clear relationship to dose timing
- Sudden, dramatic switches:
- "Off" periods: severe akinesia, nearly unable to move
- "On" periods: improved mobility but often with marked dyskinesia (choreoathetoid movements)
- Fluctuations can occur over the course of just a few hours
- The patient has very little "functional window" - time spent in a useful "on" state
- Can be highly distressing and disabling
Management:
- Protein redistribution diet (main protein meal in the evening to reduce competition with levodopa absorption)
- Adjust dose and dosing intervals
- Sustained-release levodopa formulations
- Continuous dopaminergic delivery: intrajejunal levodopa infusion or subcutaneous apomorphine infusion (reduces pulsatile stimulation)
- Subcutaneous apomorphine injection - for rescue of severe off-periods
- Inhaled levodopa (available commercially) - for intermittent treatment of off-periods
- Deep Brain Stimulation (DBS) - STN or GPi targets; modulates basal ganglia pathways and reduces off-time and dyskinesias
Summary Comparison Table
| Feature | Wearing-Off | On-Off |
|---|---|---|
| Relation to dose timing | Yes - predictable, end-of-dose | No - unpredictable |
| Mechanism | Pharmacokinetic (falling plasma levodopa) | Pharmacodynamic + network instability |
| Onset | Gradual deterioration toward end of dose interval | Sudden switches |
| Predictability | Predictable | Unpredictable |
| Stage of disease | Earlier complication | Later, more advanced disease |
| "Off" state | Return of parkinsonism symptoms | Severe akinesia |
| "On" state | Good motor control | Mobility + dyskinesia |
| Key management | COMT inhibitors, MAO-B inhibitors, dose frequency | Apomorphine, continuous infusion, DBS |
Sources:
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - "Dyskinesias and Response Fluctuations" section
- Bradley and Daroff's Neurology in Clinical Practice - "PARKINSONISM" and "PARKINSON DISEASE" sections
- Neuroanatomy through Clinical Cases, 3rd Ed. - "Parkinson's Disease and Related Disorders"
- Harrison's Principles of Internal Medicine, 22nd Ed. - "Diagnosis and Differential Diagnosis"
This is a shared conversation. Sign in to Orris to start your own chat.